Prime Medicine, Inc. PRME
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- +36.02%
- 1 year
- +8.51%
- Open
- 5.03
- Prev close
- 5.24
- Mkt cap
- 856.10M
- Vol
- 6.57M
- Avg vol
- 4.05M
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.68
- High
- 5.20
- Forward P/E
- -3.96
- Beta
- 2.67
- Short ratio
- 5.85
- Inst. own
- 44.38%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.61
- 200-d avg
- 2.96
- 1y target
- 6.50
5D chart
Signals (77)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 9:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
News
3 days ago zacks.com
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
2 weeks ago businesswire.com
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate…
2 weeks ago zacks.com
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
3 weeks ago seekingalpha.com
Leading Indicators For The October Breakout Cycle
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have…
3 weeks ago benzinga.com
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…
3 weeks ago benzinga.com
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
3 weeks ago globenewswire.com
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q…
1 month ago benzinga.com
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New…
1 month ago benzinga.com
Prime Medicine Gets FDA Green Light for Gene Editing Study
The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.
1 month ago benzinga.com
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.
1 month ago benzinga.com
Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…
-
1 month ago benzinga.com
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a ---- Initial clinical data expected…
1 month ago globenewswire.com
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago seekingalpha.com
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Prime Drink Group Provides Bi-Weekly MCTO Status Report
MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026,…
1 month ago globenewswire.com
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic…
2 months ago defenseworld.net
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission…
2 months ago benzinga.com
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
2 months ago seekingalpha.com
Prime Medicine: Soon In The Clinic
Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
2 months ago zacks.com
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
-
2 months ago benzinga.com
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of…
3 months ago zacks.com
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
3 months ago benzinga.com
Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a ---- PM577a targets the H1069Q mutation in the ATP7B gene, the most…
3 months ago globenewswire.com
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most…
3 months ago defenseworld.net
Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by 9.4% during the undefined quarter, according to its most recent filing with the Securities and…
3 months ago seekingalpha.com
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers…
3 months ago benzinga.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
3 months ago benzinga.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.
3 months ago benzinga.com
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX
-
3 months ago benzinga.com
Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam
-- Arbitration tribunal declared that PM647 is within Prime Medicine’s "Field", confirming Prime Medicine’s right to develop and commercialize PM647 in AATD ---- Prime Medicine owes no monetary…
3 months ago globenewswire.com
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary…
4 months ago benzinga.com
Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday
Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: QuidelOrtho, FuelCell, Ouster, Viasat, Swarmer, Charter, Prime Medicine, Roblox, Satellogic, Churchill…
4 months ago benzinga.com
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.
-
4 months ago benzinga.com
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
-
4 months ago benzinga.com
Prime Medicine Says FDA Grants Regenerative Medicine Advanced Therapy Designation To PM359, Investigational Autologous Prime Edited Hematopoietic Stem Cell Therapy For Treatment Of p47phox-deficient CGD
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in…
4 months ago globenewswire.com
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in…
-
4 months ago benzinga.com
Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson Disease
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the New Zealand Medicines…
5 months ago benzinga.com
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
-
5 months ago benzinga.com
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40)…
-
7 months ago benzinga.com
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
-
10 months ago benzinga.com
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
-
10 months ago benzinga.com
Prime Medicine Announced New England Journal Of Medicine Publication Of PM359 Clinical Data For Two Patients For Treatment Of Chronic Granulomatous Disease
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2…
-
11 months ago benzinga.com
Citigroup Maintains Neutral on Prime Medicine, Lowers Price Target to $4.25
Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and lowers the price target from $5 to $4.25.
-
11 months ago benzinga.com
Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $9
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $10 to $9.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session